• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 刺突蛋白中的 N501Y 和 K417N 突变改变了与 hACE2 和人源抗体的相互作用:基于扰动自由能的回溯研究。

N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study.

机构信息

Micar Innovation (Micar21) Ltd., Persenk 34B, 1407 Sofia, Bulgaria.

Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, 1101 N Campbell Street, El Paso, Texas 79968, United States.

出版信息

J Chem Inf Model. 2021 Dec 27;61(12):6079-6084. doi: 10.1021/acs.jcim.1c01242. Epub 2021 Nov 22.

DOI:10.1021/acs.jcim.1c01242
PMID:34806876
Abstract

The N501Y and K417N mutations in the spike protein of SARS-CoV-2 and their combination gave rise to questions, but the data on their mechanism of action at the molecular level were limited. In this study, we present free energy perturbation (FEP) calculations, performed at the end of December 2020, for the interactions of the spike S1 receptor-binding domain (RBD) with both the ACE2 receptor and an antibody derived from COVID-19 patients. Our results showed that the S1 RBD-ACE2 interactions were significantly increased whereas those with the STE90-C11 antibody dramatically decreased. The K417N mutation in a combination with N501Y fully abolished the antibody effect. However, Lys417Asn seems to have a compensatory mechanism of action increasing the S1 RBD-ACE2 free energy of binding. This may explain the increased spread of the virus observed in the U.K. and South Africa and also gives rise to an important question regarding the possible human immune response and the success of the already available vaccines. Notably, when the experimental data became available confirming our calculations, it was demonstrated that protein-protein FEP can be a useful tool for providing urgent data to the scientific community.

摘要

SARS-CoV-2 刺突蛋白中的 N501Y 和 K417N 突变及其组合引发了诸多疑问,但关于其在分子水平上作用机制的数据有限。在这项研究中,我们展示了 2020 年 12 月底进行的自由能微扰(FEP)计算,用于研究刺突 S1 受体结合域(RBD)与 ACE2 受体和 COVID-19 患者来源的抗体的相互作用。我们的结果表明,S1 RBD-ACE2 的相互作用显著增强,而与 STE90-C11 抗体的相互作用则急剧下降。N501Y 与 K417N 突变的组合完全消除了抗体的作用。然而,Lys417Asn 似乎具有一种补偿作用机制,增加了 S1 RBD-ACE2 的结合自由能。这可能解释了在英国和南非观察到的病毒传播增加,也引发了一个关于可能的人体免疫反应和现有疫苗成功的重要问题。值得注意的是,当实验数据证实了我们的计算结果时,证明了蛋白质-蛋白质 FEP 可以成为向科学界提供紧急数据的有用工具。

相似文献

1
N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study.SARS-CoV-2 刺突蛋白中的 N501Y 和 K417N 突变改变了与 hACE2 和人源抗体的相互作用:基于扰动自由能的回溯研究。
J Chem Inf Model. 2021 Dec 27;61(12):6079-6084. doi: 10.1021/acs.jcim.1c01242. Epub 2021 Nov 22.
2
Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor.结构、动力学及点突变对 SARS-CoV-2 刺突蛋白与 ACE2 受体结合影响的自由能研究。
PLoS One. 2023 Oct 5;18(10):e0289432. doi: 10.1371/journal.pone.0289432. eCollection 2023.
3
Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.N501Y 突变的 SARS-CoV-2 刺突蛋白与人 ACE2 受体增强结合的分子动力学模拟研究。
FEBS Lett. 2021 May;595(10):1454-1461. doi: 10.1002/1873-3468.14076. Epub 2021 Apr 3.
4
Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins.解析 SARS-CoV-2 刺突与人、猫和狗 ACE2 蛋白结合变异性的分子机制。
Phys Chem Chem Phys. 2021 Jun 28;23(24):13752-13759. doi: 10.1039/d1cp01611c. Epub 2021 Jun 15.
5
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点,用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
6
Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2.一种致死性适应鼠类的 SARS-CoV-2 的特征描述和结构基础。
Nat Commun. 2021 Sep 27;12(1):5654. doi: 10.1038/s41467-021-25903-x.
7
Corilagin and 1,3,6-Tri--galloy-β-D-glucose: potential inhibitors of SARS-CoV-2 variants.鞣花酸和 1,3,6-三没食子酰基-β-D-葡萄糖:新型冠状病毒变体的潜在抑制剂。
Phys Chem Chem Phys. 2021 Jul 14;23(27):14873-14888. doi: 10.1039/d1cp01790j.
8
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.针对关注的 SARS-CoV-2 变体的中和抗体的表位分类和 RBD 结合特性。
Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021.
9
Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.通过 GRP78 的识别在 SARS-CoV-2 的英国、南非和巴西变异株中增强;一种计算机模拟的观点。
Biochem Biophys Res Commun. 2021 Jul 12;562:89-93. doi: 10.1016/j.bbrc.2021.05.058. Epub 2021 May 21.
10
Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation.计算分解揭示了表达 N501Y 突变的 SARS-CoV-2-ACE2 界面在病毒变异体中的重塑。
J Cell Biochem. 2021 Dec;122(12):1863-1872. doi: 10.1002/jcb.30142. Epub 2021 Sep 13.

引用本文的文献

1
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中宿主硫酸乙酰肝素蛋白聚糖的治疗性开发。
Front Med (Lausanne). 2024 Mar 27;11:1364657. doi: 10.3389/fmed.2024.1364657. eCollection 2024.
2
Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response.反复出现的 SARS-CoV-2 变体:后疫情时代、合并感染和免疫反应的最新进展。
Nanotheranostics. 2024 Feb 25;8(2):247-269. doi: 10.7150/ntno.91910. eCollection 2024.
3
Within-host evolution of SARS-CoV-2: how often are mutations transmitted from symptomatic infections?
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的宿主内进化:有症状感染中产生的突变传播频率如何?
Virus Evol. 2024 Feb 21;10(1):veae006. doi: 10.1093/ve/veae006. eCollection 2024.
4
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants.新兴疫苗面临的挑战及针对 SARS-CoV-2 变异株的未来有前景的候选疫苗。
J Immunol Res. 2024 Jan 25;2024:9125398. doi: 10.1155/2024/9125398. eCollection 2024.
5
Introduction, Dispersal, and Predominance of SARS-CoV-2 Delta Variant in Rio Grande do Sul, Brazil: A Retrospective Analysis.巴西南里奥格兰德州严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)德尔塔变异株的引入、传播及优势情况:一项回顾性分析
Microorganisms. 2023 Dec 7;11(12):2938. doi: 10.3390/microorganisms11122938.
6
Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective.严重急性呼吸综合征冠状病毒2刺突蛋白的序列与结构演变:动态视角
ACS Omega. 2023 Jun 21;8(26):23283-23304. doi: 10.1021/acsomega.3c00944. eCollection 2023 Jul 4.
7
SARS CoV-2 spike protein variants exploit DC-SIGN/DC-SIGNR receptor for evolution and severity: an in-silico insight.严重急性呼吸综合征冠状病毒2刺突蛋白变体利用DC-SIGN/DC-SIGNR受体进行进化和导致疾病严重程度:计算机模拟见解
Virusdisease. 2023 May 24;34(2):1-19. doi: 10.1007/s13337-023-00820-3.
8
Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor.比较 SARS-CoV-2 刺突变异株受体结合域的差异与其与人 ACE2 受体相互作用的关系。
Sci Rep. 2023 May 30;13(1):8743. doi: 10.1038/s41598-023-35070-2.
9
The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice.通过小鼠mRNA免疫筛选靶向SARS-CoV-2刺突蛋白的广谱中和抗体
Pharmaceutics. 2023 May 5;15(5):1412. doi: 10.3390/pharmaceutics15051412.
10
Wastewater surveillance of SARS-CoV-2 genomic populations on a country-wide scale through targeted sequencing.通过靶向测序对全国范围内的 SARS-CoV-2 基因组种群进行污水监测。
PLoS One. 2023 Apr 21;18(4):e0284483. doi: 10.1371/journal.pone.0284483. eCollection 2023.